RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study

INTRODUCTION: A unique anti-interleukin (IL)-13 monoclonal antibody, RPC4046, was generated on the basis of differential IL-13 receptor (R) blockade as assessed in a murine asthma model; the safety, tolerability, pharmacokinetics, and pharmacodynamics of RPC4046 were evaluated in a first-in-human st...

Descripción completa

Detalles Bibliográficos
Autores principales: Tripp, Catherine S., Cuff, Carolyn, Campbell, Andrew L., Hendrickson, Barbara A., Voss, Jeff, Melim, Terry, Wu, Chengbin, Cherniack, Andrew D., Kim, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487860/
https://www.ncbi.nlm.nih.gov/pubmed/28455782
http://dx.doi.org/10.1007/s12325-017-0525-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487860/
https://www.ncbi.nlm.nih.gov/pubmed/28455782
http://dx.doi.org/10.1007/s12325-017-0525-8

Ejemplares similares